Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

被引：13

作者：

Armando, Calogero ^{[1
]}

Evangelista, Sagnelli ^{[2
]}

Massimiliano, Creta ^{[3
]}

Silvia, Angeletti ^{[4
]}

Gaia, Peluso ^{[1
]}

Paola, Incollingo ^{[1
]}

Maria, Candida ^{[1
]}

Gianluca, Minieri ^{[1
]}

Nicola, Carlomagno ^{[1
]}

Anna, Dodaro Concetta ^{[1
]}

Massimo, Ciccozzi ^{[5
]}

Caterina, Sagnelli ^{[2
]}

机构：

[1] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Publ Med, Naples, Italy

[3] Univ Naples Federico II, Dept Neurosci Human Reprod & Odontostomatol, Naples, Italy

[4] Univ Campus Biomed Rome, Unit Clin Lab Sci, Rome, Italy

[5] Univ Campus Biomed, Unit Med Stat & Mol Epidemiol, Rome, Italy

来源：

BIOMED RESEARCH INTERNATIONAL | 2019年 / 2019卷

关键词：

CHRONIC LIVER-DISEASES; HEPATITIS-C INFECTION; KIDNEY-TRANSPLANTATION; TOLERABILITY; EXPERIENCE; EFFICACY; IMPACT;

D O I：

10.1155/2019/4674560

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Hepatitis C virus (HCV) infection unfavorably affects the survival of both renal patients undergoing hemodialysis and renal transplant recipients. In this subset of patients, the effectiveness and safety of different combinations of interferon-free direct-acting antiviral agents (DAAs) have been analyzed in several small studies. Despite fragmentary, the available data demonstrate that DAA treatment is safe and effective in eradicating HCV infection, with a sustained virologic response (SVR) rates nearly 95% and without an increased risk of allograft rejection. This review article analyzes the results of most published studies on this topic to favor more in-depth knowledge of the readers on the subject. We suggest, however, perseverating in this update as the optimal DAA regimen may not be proposed yet, because of the expected arrival of newer DAAs and of the lack of data from large multicenter randomized controlled trials.

引用

页数：8

共 105 条

[71] Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [J].

Roth, David ;

Nelson, David R. ;

Bruchfeld, Annette ;

Liapakis, AnnMarie ;

Silva, Marcelo ;

Monsour, Howard, Jr. ;

Martin, Paul ;

Pol, Stanislas ;

Londono, Maria-Carlota ;

Hassanein, Tarek ;

Zamor, Philippe J. ;

Zuckerman, Eli ;

Wan, Shuyan ;

Jackson, Beth ;

Nguyen, Bach-Yen ;

Robertson, Michael ;

Barr, Eliav ;

Wahl, Janice ;

Greaves, Wayne .

LANCET, 2015, 386 (10003) :1537-1545

[72] Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis [J].

Saab, S ;

Martin, P ;

Brezina, M ;

Gitnick, G ;

Yee, HF .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (02) :308-315

[73] Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C [J].

Sagnelli, C. ;

Merli, M. ;

Uberti-Foppa, C. ;

Hasson, H. ;

Cirillo, G. ;

Grandone, A. ;

Salpietro, S. ;

Minichini, C. ;

Del Giudice, E. M. ;

Lazzarin, A. ;

Sagnelli, E. ;

Coppola, N. .

CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (04) :372-378

[74] Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection [J].

Sagnelli, C. ;

Uberti-Foppa, C. ;

Pasquale, G. ;

De Pascalis, S. ;

Coppola, N. ;

Albarello, L. ;

Doglioni, C. ;

Lazzarin, A. ;

Sagnelli, E. .

INFECTION, 2013, 41 (05) :959-967

[75] Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients [J].

Sagnelli, Caterina ;

Uberti-Foppa, Caterina ;

Hasson, Hamid ;

Bellini, Giulia ;

Minichini, Carmine ;

Salpietro, Stefania ;

Messina, Emanuela ;

Barbanotti, Diletta ;

Merli, Marco ;

Punzo, Francesca ;

Coppola, Nicola ;

Lazzarin, Adriano ;

Sagnelli, Evangelista ;

Rossi, Francesca .

PLOS ONE, 2017, 12 (07)

[76] TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype [J].

Sagnelli, Caterina ;

Merli, Marco ;

Uberti-Foppa, Caterina ;

Hasson, Hamid ;

Grandone, Anna ;

Cirillo, Grazia ;

Salpietro, Stefania ;

Minichini, Carmine ;

Starace, Mario ;

Messina, Emanuela ;

Morelli, Patrizia ;

Del Giudice, Emanuele Miraglia ;

Lazzarin, Adriano ;

Coppola, Nicola ;

Sagnelli, Evangelista .

WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (38) :8509-8518

[77] Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients [J].

Sagnelli, Caterina ;

Uberti-Foppa, Caterina ;

Galli, Laura ;

Pasquale, Giuseppe ;

Coppola, Nicola ;

Albarello, Luca ;

Doglioni, Carlo ;

Lazzarin, Adriano ;

Sagnelli, Evangelista .

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2014, 18 (02) :164-169

[78] Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma [J].

Sagnelli, Evangelista ;

Potenza, Nicoletta ;

Onorato, Lorenzo ;

Sagnelli, Caterina ;

Coppola, Nicola ;

Russo, Aniello .

WORLD JOURNAL OF HEPATOLOGY, 2018, 10 (09) :558-570

[79]

Sagnelli E, 2018, EUR J GASTROEN HEPAT, V30, P676, DOI [10.1097/MEG.0000000000001099, 10.1097/meg.0000000000001099]

[80] Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy [J].

Sagnelli, Evangelista ;

Stroffolini, Tommaso ;

Sagnelli, Caterina ;

Pirisi, Mario ;

Babudieri, Sergio ;

Colloredo, Guido ;

Russello, Maurizio ;

Coppola, Nicola ;

Gaeta, Giovanni Battista ;

Cacopardo, Bruno ;

De Luca, Massimo ;

Almasio, Piero Luigi .

INFECTION, 2018, 46 (01) :93-101

← 2 3 4 5 6 7 8 9 10 11 →